ZyVersa Therapeutics Inc (ZVSA) Actualités

Form 8-K - Current report

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

WESTON, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a...

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form DEF 14A - Other definitive proxy statements

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form PRE 14A - Other preliminary proxy statements

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies...

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with...

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Form 8-K - Current report

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]